共 189 条
[1]
Armstrong K(2004)Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis J ClinOncol 22 1045-1054
[2]
Schwartz JS(2005)Endometrial cancer and hormone-replacement therapy in the million women study Lancet 365 1543-1551
[3]
Randall T(2018)Is hormone replacement therapy safe in women with a BRCA mutation?: A systematic review of the contemporary literature Am J ClinOncol 41 313-315
[4]
Rubin SC(2019)Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence Lancet 394 1159-1168
[5]
Weber B(2016)Use of systemic hormone therapy in BRCA mutation carriers Menopause 23 1026-1027
[6]
Beral V(2010)Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality JAMA 304 967-975
[7]
Bull D(2011)Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? J ClinOncol 29 1501-1367
[8]
Reeves G(2008)Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers J Natl Cancer Inst 100 1361-1553
[9]
Birrer N(2014)Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation J ClinOncol 32 1547-65
[10]
Chinchilla C(2020)Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers Best Pract Res ClinObstetGynaecol 65 46-28